Successful Rapid Desensitization to Ceftazidime/Avibactam in a Patient With Cystic Fibrosis and Multidrug-Resistant Pseudomonas aeruginosa Pneumonia: A Case Report.

Ceftazidime/avibactam (CAZ-AVI) is an important therapeutic option for multidrug-resistant (MDR) Pseudomonas aeruginosa infections; however, hypersensitivity reactions may preclude its use and create significant therapeutic challenges. We report a 21-year-old woman with cystic fibrosis and recurrent MDR P. aeruginosa pneumonia who had a clinically suspected immediate hypersensitivity reaction to CAZ-AVI. In the absence of effective alternative antimicrobial options, a 13-step rapid intravenous desensitization protocol was performed under intensive monitoring. The patient subsequently tolerated full-dose CAZ-AVI therapy with marked clinical improvement. Rapid desensitization may represent an effective rescue strategy for patients with CAZ-AVI allergy when applied under strict clinical indications and multidisciplinary supervision.